Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BMI1
REST API REST API
Homo sapiens
BMI1 is differentially expressed in 289 experiments: 74 organism parts: bone marrow, prostate, ... (72 more);, 150 disease states: normal, control, ... (148 more);, 88 cell types 375 cell lines 21 compound treatments and 71 other conditions.
Synonyms PCGF4, RNF51
Orthologs BMI1_BOVIN (Bos taurus)   Bmi1 (Rattus norvegicus)   bmi1b (Danio rerio)   Bmi1 (Mus musculus)   bmi1 (Danio rerio)   Psc (Drosophila melanogaster)   bmi1 (Xenopus laevis)   MSS11 (Saccharomyces cerevisiae)   BMI1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term segment specification, humoral immune response, protein binding, regulation of transcription, DNA-dependent, cytoplasm, somatic stem cell division, negative regulation of apoptosis, metal ion binding, PRC1 complex, hemopoiesis, nucleus, histone acetylation, regulation of gene expression, ubiquitin-protein ligase activity, ubiquitin ligase complex, PcG protein complex, nuclear body, chromatin binding, chromatin modification, histone ubiquitination, negative regulation of transcription from RNA polymerase II promoter, brain development, nucleolus, zinc ion binding, positive regulation of B cell proliferation, in utero embryonic development, embryonic skeletal system morphogenesis, embryonic skeletal system development, positive regulation of fibroblast proliferation, skeletal system development, positive regulation of ubiquitin-protein ligase activity, RING-like zinc finger domain binding, rostrocaudal neural tube patterning, positive regulation of immature T cell proliferation in thymus
InterPro Term Znf_RING, Znf_C3HC4_RING-type
UniProt Accession P35226, Q5T8Z2, Q5T8Z1, Q5T8Z5, Q5T8Z4, Q5T8Z6, C9JKW4, E9PC92
Search EB-eye ENSG00000168283
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (48 experiments)

Factor Value U/D Experiments
T84
2
E-GEOD-1474, E-MTAB-37
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-7
2
E-GEOD-3529, E-GEOD-5823
MOLT4
2
E-MTAB-62, E-MTAB-37
Raji
2
E-MTAB-37, E-GEOD-96
ANBL-6
1
E-MEXP-921
369 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-13909, E-GEOD-20677, ... (46 experiments)

Factor Value U/D Experiments
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
82 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, ... (57 experiments)

Factor Value U/D Experiments
multiple myeloma
3
E-MTAB-62, E-GEOD-6691, E-GEOD-2113
acute myeloid leukemia
1
2
E-MTAB-62, E-GEOD-995, E-MEXP-25
acute lymphoblastic leukemia
1
2
E-GEOD-96, E-MTAB-62, E-MTAB-37
spindle cell carcinoma
1
E-MTAB-62
monophasic synovial sarcoma
1
E-MTAB-62
colorectal cancer
1
E-GEOD-15960
144 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, E-TABM-868, ... (15 experiments)

Factor Value U/D Experiments
none
2
6
E-GEOD-5824, E-GEOD-7400, E-GEOD-412, E-TABM-868, E-GEOD-2649, ... (8 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
1mM GDC-0941
1
E-GEOD-20719
hydrogen peroxide
1
E-GEOD-5339
SDF
1
E-GEOD-7307
phenol
1
E-GEOD-6907
15 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-860, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-19665, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-GEOD-2292, E-TABM-321, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-TABM-127, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (6 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.338 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM